Rocketing restoration : enabling the upscaling of ecological restoration in the Anthropocene

In the 25 years during which the Society for Ecological Restoration (SER) has overseen the publication of Restoration Ecology, the field has witnessed conceptual and practical advances. These have become necessary due to the scale of environmental change wrought by the increasing global human population, and associated demands for food, fiber, energy, and water. As we look to the future, and attempt to fulfill global restoration commitments and meet sustainable development goals, there is a need to reverse land degradation and biodiversity loss through upscaling ecological restoration. Here, we argue that this upscaling requires an expanded vision for restoration that explicitly accounts for people and nature. This expansion can assess success in a future-focused way and as improvements relative to a degraded socio-ecological system. We suggest that upscaling requires addressing governance, legal and ethical challenges, investing in technological and educational capacity building, bolstering the practical science necessary for restoration, encouraging adoptable packages to ensure livelihoods of local stakeholders, and promoting investment opportunities for local actors and industry. Providing SER embraces this socio-ecological vision, it is ideally placed to aid the achievement of goals and remain globally relevant. SER needs to harness and coordinate three sources of potential energy (global political commitments, the green economy, and local community engagement) to rocket restoration into the Anthropocene. With principles that can embrace flexibility and context-dependency in minimum restoration standards, SER has the potential to guide socio-ecological restoration and help realize the ultimate goal of a sustainable Earth

Photocatalytic and biomedical investigation of green synthesized NiONPs: Toxicities and degradation pathways of Congo red dye

In this study the biomedical and catalytic ability of green synthesized nickel Oxide nanoparticles (NiONPs) was investigated. The extract of medicinal plant Tribulus terrestris were used to synthesized NiONPs. The as-synthesized NiONPs were in nano scale and were characterized with X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FTIR), High-Resolution Transmission Electron Microscopy (HRTEM), Scanning Electron Microscope (SEM), X-ray photoelectron spectroscopy (XPS) and Energy Dispersive X-ray spectroscopy (EDX). The synthesis of NiONPs was ensured with surface Plasmon resonance (SPR) at 425 nm and the strong EDX. The effect of different concentrations of plant extract on the size of NiONPs was evaluated. The HRTEM results showed particle size between 60 - 90 nm. The study showed that lesser the extract concentration, more spherical and small sized particles were obtained without aggregation. The biological applications of NiONPs were evaluated against different fungal species like Asper gillusflavus, Asper gillusfumigatus, Asper gillusniger and standard medicine Terbinafine. A. niger, A. flavus and A. fumigatus exhibited 57, 63 and 52 % inhibition compared with inhibition of the reference medicine which is 98, 100 and 100%. NiONPs have been shown to be more effective against gram-positive bacteria than gram-negative bacteria like E. Coli 9(±0.7) and S. aureus13 (±0.8). Moreover, antioxidant properties of the as-synthesized NiONPs were evaluated with 2, 2 diphenyl-1-picrylhydrazyl) (DPPH). The catalytic ability of green synthesized of NiONP was investigated for the degradation of Congo red dye (CR) as a hazardous environmentally contaminations in water. The biosynthesized NiONPs were found to be active catalytic for the degradation toxic dyes like CR. the catalytic activity of NiONPs can be explained by its small size compared with balk material. Mechanisms for CR degradation have been proposed. The Ecotoxicity of CR and components derived from dye was investigated with Ecological Structure Activity Relationship (ECOSAR) program

Establishing an online resource to facilitate global collaboration and inclusion of underrepresented populations:Experience from the MJFF Global Genetic Parkinson's Disease Project

Parkinson's disease (PD) is the fastest-growing neurodegenerative disorder, currently affecting ~7 million people worldwide. PD is clinically and genetically heterogeneous, with at least 10% of all cases explained by a monogenic cause or strong genetic risk factor. However, the vast majority of our present data on monogenic PD is based on the investigation of patients of European White ancestry, leaving a large knowledge gap on monogenic PD in underrepresented populations. Gene-targeted therapies are being developed at a fast pace and have started entering clinical trials. In light of these developments, building a global network of centers working on monogenic PD, fostering collaborative research, and establishing a clinical trial-ready cohort is imperative. Based on a systematic review of the English literature on monogenic PD and a successful team science approach, we have built up a network of 59 sites worldwide and have collected information on the availability of data, biomaterials, and facilities. To enable access to this resource and to foster collaboration across centers, as well as between academia and industry, we have developed an interactive map and online tool allowing for a quick overview of available resources, along with an option to filter for specific items of interest. This initiative is currently being merged with the Global Parkinson's Genetics Program (GP2), which will attract additional centers with a focus on underrepresented sites. This growing resource and tool will facilitate collaborative research and impact the development and testing of new therapies for monogenic and potentially for idiopathic PD patients.</p

Envejecimiento de la población

&bull;Actividades b&aacute;sicas de la vida diaria en personas mayores y factores asociados &bull;Asociaci&oacute;n entre depresi&oacute;n y posesi&oacute;n de mascotas en personas mayores &bull;Calidad de vida en adultos mayores de Santiago aplicando el instrumento WHOQOL-BREF &bull;Calidad de vida en usuarios con enfermedad de Parkinson, demencia y sus cuidadores, comuna de Vitacura &bull;Caracterizaci&oacute;n de egresos hospitalarios de adultos mayores en Puerto Natales (2007-2009) &bull;Comportamiento de las patolog&iacute;as incluidas como GES para el adulto mayor atendido en un Cesfam &bull;Contribuci&oacute;n de vitaminas y minerales a las ingestas recomendadas diarias en ancianos institucionalizados de Madrid &bull;Estado de salud oral del paciente inscrito en el Programa de Visita Domiciliaria &bull;Evaluaci&oacute;n del programa de discapacidad severa en Casablanca con la matriz de marco l&oacute;gico &bull;Factores asociados a satisfacci&oacute;n vital en una cohorte de adultos mayores de Santiago, Chile &bull;Pauta instrumental para la identificaci&oacute;n de riesgos para el adulto mayor autovalente, en su vivienda &bull;Perfil farmacol&oacute;gico del paciente geri&aacute;trico institucionalizado y posibles consecuencias en el deterioro cognitivo &bull;Programa de cuidados paliativos y alivio del dolor en Puerto Natales &bull;Rehabilitaci&oacute;n mandibular implantoprot&eacute;sica: efecto en calidad de vida relacionada con salud bucal en adultos mayores &bull;Salud bucodental en adultos mayores autovalentes de la Regi&oacute;n de Valpara&iacute;so &bull;Transici&oacute;n epidemiol&oacute;gica y el estudio de carga de enfermedad en Brasi

Early mobilisation in critically ill COVID-19 patients: a subanalysis of the ESICM-initiated UNITE-COVID observational study

Background Early mobilisation (EM) is an intervention that may improve the outcome of critically ill patients. There is limited data on EM in COVID-19 patients and its use during the first pandemic wave. Methods This is a pre-planned subanalysis of the ESICM UNITE-COVID, an international multicenter observational study involving critically ill COVID-19 patients in the ICU between February 15th and May 15th, 2020. We analysed variables associated with the initiation of EM (within 72 h of ICU admission) and explored the impact of EM on mortality, ICU and hospital length of stay, as well as discharge location. Statistical analyses were done using (generalised) linear mixed-effect models and ANOVAs. Results Mobilisation data from 4190 patients from 280 ICUs in 45 countries were analysed. 1114 (26.6%) of these patients received mobilisation within 72 h after ICU admission; 3076 (73.4%) did not. In our analysis of factors associated with EM, mechanical ventilation at admission (OR 0.29; 95% CI 0.25, 0.35; p = 0.001), higher age (OR 0.99; 95% CI 0.98, 1.00; p ≤ 0.001), pre-existing asthma (OR 0.84; 95% CI 0.73, 0.98; p = 0.028), and pre-existing kidney disease (OR 0.84; 95% CI 0.71, 0.99; p = 0.036) were negatively associated with the initiation of EM. EM was associated with a higher chance of being discharged home (OR 1.31; 95% CI 1.08, 1.58; p = 0.007) but was not associated with length of stay in ICU (adj. difference 0.91 days; 95% CI − 0.47, 1.37, p = 0.34) and hospital (adj. difference 1.4 days; 95% CI − 0.62, 2.35, p = 0.24) or mortality (OR 0.88; 95% CI 0.7, 1.09, p = 0.24) when adjusted for covariates. Conclusions Our findings demonstrate that a quarter of COVID-19 patients received EM. There was no association found between EM in COVID-19 patients' ICU and hospital length of stay or mortality. However, EM in COVID-19 patients was associated with increased odds of being discharged home rather than to a care facility. Trial registration ClinicalTrials.gov: NCT04836065 (retrospectively registered April 8th 2021)